Figure 5.

Combination therapy with rAd-p53 and anti-PD-1 antibody in the TRAMP-C2 syngeneic tumor model. Two million TRAMP-C2 cells were subcutaneously inoculated into C57BL/6 mice at day 0. 1 × 10⁹ PFU of rAd-p53, rAd-LacZ or PBS were intratumorally injected every other day starting 53 days after tumor inoculation (n = 5). Anti-PD-1 antibody was intraperitoneally injected twice a week (6 times total) starting 56 days after tumor inoculation: (a) a schematic drawing of the treatment. (b) Tumor growth curves of individual mice in each treatment group. Open circles are mice alive at day 140. (c) Kaplan–Meier survival curve post tumor inoculation. The combination therapy of rAd-p53 and anti-PD-1 antibody substantially prolonged survival compared to other treatments.